Table 2. Summary of the results after hemolymph, bacterial, baculovirus-mediated dsJHER administration.
Type of administration | Targeted region | Time of administration | Total insects* | Control | Total insects* (Controltreatments) | Specific SnJHER silencing | Phenotype |
Injection | 472 bp | 5thd3 | 100 | dsL4440MCS | 100 | Yes | Absent |
1276 bp | 5thd3 | 100 | dsL4440MCS | 100 | Yes | Absent | |
1725 bp | 5thd3 | 100 | dsL4440MCS | 100 | Yes | 5% of melanized/fused epidermis | |
472 bp | 6thd9 | 100 | dsL4440MCS | 100 | Yes | >90% of larval-pupal intermediates type I. | |
1276 bp | 6thd9 | 100 | dsL4440MCS | 100 | Yes | >90% of larval-pupal intermediates type II. | |
1725 bp | 6thd9 | 100 | dsL4440MCS | 100 | Yes | >90% of larval-pupal intermediates type III. | |
Bacterial feeding | 472 bp | 1std05thd0 | 100 | HT115-L4440 | 100 | Yes | Absent |
472 bp | 1std06thd9 | 100 | HT115-L4440 | 100 | Yes | Absent | |
472 bp | 5thd05thd7 | 100 | HT115-L4440 | 100 | Yes | Absent | |
Baculovirus infection | 472 bp | 5thd3 | 200 | dsLuciferase Virus | 200 | Yes | 14% of melanized/fused epidermis |
472 bp | 6thd9 | 200 | dsLuciferase Virus | 200 | Yes | 21% of larval-pupal intermediates type 3 | |
472 bp | Survived pupae from 6thd9 infections | 78 | dsLuciferase Virus | 62 | Yes | 9% of scale-less adults |
The asterisk indicates the total amount of insects used, among three independent trials, both for control and experimental groups.